Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA: Extracorporeal Photopheresis (ECP) in Type 1 Diabetes Mellitus
NCT05413005Phase 1Active, not recruiting
- Sponsor
- Abu Dhabi Stem Cells Center
- Start
- Sep 2022
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Abu Dhabi Stem Cells Center. Primary endpoints: Tolerability to ECP procedures, Incidence of adverse events and 4 more. Started Sep 2022; status: active, not recruiting.
02
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05413005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413005.